Next-Generation Durable Design:

The mechanical therapy provided by Zilver PTX counteracts acute recoil to maintain patency. The 12-month fracture rate of this stent was just 0.9% in the randomized trial (core-lab adjudicated).1

  • Linear-cell stent design delivers stable on-target deployment.
  • Meticulous electropolishing provides superior fracture resistance.
  • Strength and flexibility are balanced for exceptional stent durability in the dynamic anatomy of the SFA.
ZilverPTXDurability
1 Dake M. The Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease: 24-month update. Presented at: 7th edition of the Leipzig Interventional Course (LINC) 2011; January 19-22, 2011; Leipzig, Germany.

Instructions for Use:

Please refer to the Zilver PTX IFU for indications, contraindications, warnings, precautions and potential adverse events. PDF Download »

Explore the data from the Zilver PTX clinical trials.
Available in 6 Fr and lengths up to 120 mm.

Available in 6 Fr and lengths up to 120 mm.